drugset / Trial / NCT00800267

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

NCT00800267

Phase 3 Completed 418 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety and efficacy study comparing between fixed combination latanoprost-timolol and its component parts.

Timeline

Start
1997-07
Primary completion
1999-06
Completion
1999-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule 0.005 %
Subject Timolol Other / unclassified 0.5 %